Sanofi/Aventis Merger Would Create Top 10 U.S. Pharma Company
Executive Summary
A Sanofi/Aventis merger combination would break Sanofi into the top 10 ranking of U.S. pharmaceutical companies
You may also be interested in...
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call
Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control
Sanofi's winning bid for Aventis includes an additional $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call